Gilead buys into multiple myeloma cell therapy with Arcellx deal
On Friday, alongside its deal with Kite, Arcellx disclosed new data from an early-stage study testing its medicine in patients with relapsed or refractory multiple myeloma. Arcellx said 38 participants were able to be evaluated for safety and efficacy as of Oct. 31. All responded to its treatment. Four patients achieved a partial response, while another seven had a “very good” partial response. The remaining 27 had a complete or “stringent complete” response.
Arcellx noted how these patients came into the study with “poor prognostic factors.” All 38 of them had previously tried at least three therapies, and 26 had their disease progress after five prior treatments.
Rami Elghandour, Arcellx’s CEO, said in a statement that these latest results further support his company’s decision to initiate a mid-stage trial, which recently dosed its first patients. That trial is expected to produce initial results in mid-2024.
